Opaleye Management Inc. Autolus Therapeutics PLC Transaction History

Opaleye Management Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$4.78 - $7.96 $10.1 Million - $16.8 Million	-2,112,918 Closed	0 $0
Q1 2021 May 18, 2021	BUY	$5.49 - $9.36 $11.6 Million - $19.8 Million	2,112,918 New	2,112,918 $12.1 Million
Q3 2020 Nov 16, 2020	SELL	$11.64 - $16.3 $698,400 - $978,000	-60,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$5.38 - $16.14 $322,800 - $968,400	60,000 New	60,000 $962,000

115

166M

34.2K

19.5K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $395M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.